Stockreport

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial

Syndax Pharmaceuticals, Inc.  (SNDX) 
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.syndax.com
PDF – Subgroup analyses from Ph 2 protocol-defined R/R mNPM1 AML efficacy population (N=64) show responses across all major subgroups, including heavily pretreated patients [Read more]